Athersys Inc. (NASDAQ:ATHX)’s share price traded down 2.2% during trading on Thursday . The stock traded as low as $2.16 and last traded at $2.21, with a volume of 349,642 shares traded. The stock had previously closed at $2.26.

Several equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Monday. Maxim Group reissued a “buy” rating on shares of Athersys in a report on Monday, June 27th. Finally, TheStreet raised shares of Athersys from a “sell” rating to a “hold” rating in a report on Tuesday, May 31st.

The stock’s 50 day moving average price is $2.24 and its 200-day moving average price is $1.95. The firm has a market cap of $186.44 million and a P/E ratio of 221.00.

Athersys (NASDAQ:ATHX) last issued its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.14. The company earned $15.45 million during the quarter, compared to analysts’ expectations of $1.85 million. The firm’s quarterly revenue was up 2016.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.16) earnings per share. On average, analysts forecast that Athersys Inc. will post ($0.23) EPS for the current year.

In other Athersys news, COO William Lehmann, Jr. sold 25,000 shares of Athersys stock in a transaction dated Tuesday, June 21st. The stock was sold at an average price of $2.17, for a total value of $54,250.00. Following the completion of the transaction, the chief operating officer now directly owns 279,017 shares of the company’s stock, valued at approximately $605,466.89. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.